252 related articles for article (PubMed ID: 15131789)
1. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity.
Chalasani N; Aljadhey H; Kesterson J; Murray MD; Hall SD
Gastroenterology; 2004 May; 126(5):1287-92. PubMed ID: 15131789
[TBL] [Abstract][Full Text] [Related]
2. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes.
Vuppalanchi R; Teal E; Chalasani N
Am J Med Sci; 2005 Feb; 329(2):62-5. PubMed ID: 15711421
[TBL] [Abstract][Full Text] [Related]
3. Effect of rosiglitazone on serum liver biochemistries in diabetic patients with normal and elevated baseline liver enzymes.
Chalasani N; Teal E; Hall SD
Am J Gastroenterol; 2005 Jun; 100(6):1317-21. PubMed ID: 15929763
[TBL] [Abstract][Full Text] [Related]
4. Incidence of statin hepatotoxicity in patients with hepatitis C.
Khorashadi S; Hasson NK; Cheung RC
Clin Gastroenterol Hepatol; 2006 Jul; 4(7):902-7; quiz 806. PubMed ID: 16697272
[TBL] [Abstract][Full Text] [Related]
5. Statin therapy and serum transaminases among a cohort of HCV-infected veterans.
Henderson LM; Patel S; Giordano TP; Green L; El-Serag HB
Dig Dis Sci; 2010 Jan; 55(1):190-5. PubMed ID: 19731022
[TBL] [Abstract][Full Text] [Related]
6. Statin-related aminotransferase elevation according to baseline aminotransferases level in real practice in Korea.
Kim HS; Lee SH; Kim H; Lee SH; Cho JH; Lee H; Yim HW; Kim SH; Choi IY; Yoon KH; Kim JH
J Clin Pharm Ther; 2016 Jun; 41(3):266-72. PubMed ID: 27015878
[TBL] [Abstract][Full Text] [Related]
7. Liver Biochemistries in Hospitalized Patients With COVID-19.
Bloom PP; Meyerowitz EA; Reinus Z; Daidone M; Gustafson J; Kim AY; Schaefer E; Chung RT
Hepatology; 2021 Mar; 73(3):890-900. PubMed ID: 32415860
[TBL] [Abstract][Full Text] [Related]
8. The Effects of Melatonin on Elevated Liver Enzymes during Statin Treatment.
Chojnacki C; Błońska A; Chojnacki J
Biomed Res Int; 2017; 2017():3204504. PubMed ID: 28630863
[TBL] [Abstract][Full Text] [Related]
9. Change in ALT levels after administration of HMG-CoA reductase inhibitors to subjects with pretreatment levels three times the upper normal limit in clinical practice.
Kim H; Lee H; Kim TM; Yang SJ; Baik SY; Lee SH; Cho JH; Lee H; Yim HW; Choi IY; Yoon KH; Kim HS
Cardiovasc Ther; 2018 Jun; 36(3):e12324. PubMed ID: 29464863
[TBL] [Abstract][Full Text] [Related]
10. A prospective study of hepatic safety of statins used in very elderly patients.
Guo M; Zhao J; Zhai Y; Zang P; Lv Q; Shang D
BMC Geriatr; 2019 Dec; 19(1):352. PubMed ID: 31842780
[TBL] [Abstract][Full Text] [Related]
11. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels.
Tikkanen MJ; Fayyad R; Faergeman O; Olsson AG; Wun CC; Laskey R; Kastelein JJ; Holme I; Pedersen TR;
Int J Cardiol; 2013 Oct; 168(4):3846-52. PubMed ID: 24001698
[TBL] [Abstract][Full Text] [Related]
12. Liver biochemistry abnormalities in a quaternary care lipid clinic database.
Wiesinger HA; Shah J; White A; Yoshida EM; Frohlich J; Sirrs S; Gill S; Byrne MF
Ann Hepatol; 2008; 7(1):63-6. PubMed ID: 18376368
[TBL] [Abstract][Full Text] [Related]
13. Hepatotoxicity of Statins as Determined by Serum Alanine Aminotransferase in a Pediatric Cohort With Dyslipidemia.
Desai NK; Mendelson MM; Baker A; Ryan HH; Griggs S; Boghani M; Yellen E; Buckley L; Gillman MW; Zachariah JP; Graham D; Jonas MM; de Ferranti SD
J Pediatr Gastroenterol Nutr; 2019 Feb; 68(2):175-181. PubMed ID: 30334928
[TBL] [Abstract][Full Text] [Related]
14. Elevated Liver Enzymes Unmask Severe Statin-Induced Muscle Injury.
Abdallah MA; Ahmed KM; Gohar A; Abdalla AO; Waqas Q; Elgouhari H; Huntington MK
Am J Ther; 2020; 27(4):e420-e422. PubMed ID: 31180927
[No Abstract] [Full Text] [Related]
15. Hepatic effects of lovastatin exposure in patients with liver disease: a retrospective cohort study.
Avins AL; Manos MM; Ackerson L; Zhao W; Murphy R; Levin TR; Watson DJ; Hwang PM; Replogle A; Levine JG
Drug Saf; 2008; 31(4):325-34. PubMed ID: 18366243
[TBL] [Abstract][Full Text] [Related]
16. 3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor use in chronic liver disease: a therapeutic controversy.
Tzefos M; Olin JL
J Clin Lipidol; 2011; 5(6):450-9. PubMed ID: 22108148
[TBL] [Abstract][Full Text] [Related]
17. Resistant nonalcoholic fatty liver disease amelioration with rosuvastatin and pioglitazone combination therapy in a patient with metabolic syndrome.
Riche DM; Fleming JW; Malinowski SS; Black CA; Miller KH; Wofford MR
Ann Pharmacother; 2014 Jan; 48(1):137-41. PubMed ID: 24259612
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and hepatotoxicity of statins in men seropositive for hepatitis C virus.
Segarra-Newnham M; Parra D; Martin-Cooper EM
Pharmacotherapy; 2007 Jun; 27(6):845-51. PubMed ID: 17542767
[TBL] [Abstract][Full Text] [Related]
19. Liver enzymes elevation after HAART in HIV-HCV co-infection.
Servin-Abad L; Molina E; Baracco G; Arosemena L; Regev A; Jeffers L; Schiff E
J Viral Hepat; 2005 Jul; 12(4):429-34. PubMed ID: 15985015
[TBL] [Abstract][Full Text] [Related]
20. Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting.
Smith CC; Bernstein LI; Davis RB; Rind DM; Shmerling RH
Arch Intern Med; 2003 Mar; 163(6):688-92. PubMed ID: 12639201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
